Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Muthu Vaduganathan Profile picture
Muthu Vaduganathan
@mvaduganathan
Cardiologist & Trialist @BrighamWomens @harvardmed | AE @JACCJournals | Podcast #DontMissABeat & #HFinFocus | Disclosures: https://t.co/BmQHCNyLml
May 24 • 9 tweets • 4 min read
🚨#FLOW: The most anticipated trial of the year now published in @NEJM with #ERA24

Semaglutide 1.0mg once weekly disease modifying with kidney, CV, & mortality benefits in people w T2D+CKD, cementing itself as a new pillar of care.

🧵 on key thoughts 👇🏾

nejm.org/doi/full/10.10…
Image Excellent trial conduct

✅ Vital status known in 98.6%
✅ High rates of treatment adherence (89% throughout trial)
✅ Study treatment discontinuation modest (26%) but reasonable given #FLOW conducted "intra-pandemic" (recruitment June '19 to May '21) & long follow-up (3.4 years)
Jan 31, 2022 • 5 tweets • 6 min read
New in @JACCJournals w @JJheart_doc on intersection of biomarkers & #SGLT2i in #T2D.

Canagliflozin in #CANVAS
⤵️hs-cTnT & sST2 out to 6yrs
⤵️HF & kidney outcomes irrespective of baseline biomarkers
⤵️MACE particularly in those w multiple abnormal markers

jacc.org/doi/10.1016/j.… In >3K👥in #CANVAS, canagliflozin (versus PBO) reduced #hscTnT (marker of cardiac injury) & #sST2 (marker of vascular congestion, inflammation & fibrosis) out to 6yrs

Importantly, rather than reducing biomarkers below baseline, #SGLT2i appear to delay longitudinal rise after 1yr